# Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

> **NCT06494397** · PHASE1 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Schizophrenia
- Bipolar I Disorder

## Interventions

- **DRUG:** VHX-896 and iloperidone
- **DRUG:** Iloperidone and VHX-896

## Key facts

- **NCT ID:** NCT06494397
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-11
- **Primary completion:** 2024-10-24
- **Final completion:** 2024-10-24
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06494397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06494397, "Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06494397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*